News and Announcements
DeClout Incubator Launched to Support Singapore Fintech Startups
- Published April 24, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
DeClout (SXG:5UZ) has launched a new incubator program designed to help local Fintech startups. The company has recently announced that the program has been launched via its wholly owned subsidiary, DeClout Investments Pte. Ltd.
KEY TAKEAWAYS:
- Under its incubation program DeClout will mentor early-stage startups and help them in product development, proof-of-concept, commercialisation and future fundraising.
- DeClout will be engaging startups in Fintech, cybersecurity, data analytics and smart logistics as these areas are key market niches with potential for disruptive innovation.
- SPRING Singapore, an agency under the Ministry of Trade and Industry, was supporting the new incubator.
Vesmond Wong, Chairman and Group Chief Executive Officer of DeClout, said they were honoured to be grooming local Fintech and ICT startups.
“We will continue to help entrepreneurs in their startup journey. Having walked the path of an entrepreneur ourselves, we are committed to imparting our knowledge and expertise to the next generation in Singapore.”
Ted Tan, Deputy Chief Executive of SPRING Singapore, added they were happy to support the new DeClout incubation program.
“This is aligned with SPRING’s aim to encourage more corporations to take the lead in aiding the growth of startups in Singapore,” said Tan. “With DeClout’s track record of successfully scaling businesses into global players, we look forward to its progressive role in enhancing our startup ecosystem.”
DeClout currently operates two core business segments: IT Infrastructure Sales and Services and Vertical Domain Clouds – out of Singapore, Malaysia, Indonesia, Thailand, Myanmar, India, Kenya, the United States (“US”), the United Kingdom (“UK”) and the People’s Republic of China.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
